Table 5.

MIC₅₀, MIC₉₀ and MIC range (mg/L) of, and antimicrobial susceptibility and resistance to, ceftazidime/avibactam and selected comparator agents for P. aeruginosa and MDR P. aeruginosa, collected in individual Latin America countries as part of the INFORM study^a, 2015–17

Country/antimicrobial	MIC50 (mg/L)	MIC90 (mg/L)	MIC range (mg/L)	S (%)	R (%)
Argentina (N = 345)
All P. aeruginosa
ceftazidime/avibactam	2	8	0.25 to ≥256	94.5	5.5
imipenem	2	≥16	0.25 to ≥16	75.7	24.3
meropenem	0.5	≥16	0.03 to ≥16	70.1	15.4
colistin	1	1	≤0.06 to 8	99.7	0.3
amikacin	4	≥64	1 to ≥64	82.3	13.3
MDR (N = 101)
ceftazidime/avibactam	8	16	0.5 to ≥256	81.2	18.8
imipenem	≥16	≥16	0.25 to ≥16	37.6	62.4
meropenem	8	≥16	0.25 to ≥16	17.8	49.5
colistin	1	2	≤0.06 to 8	99.0	1.0
amikacin	16	≥64	1 to ≥64	49.5	41.6
Brazil (N = 346)
All P. aeruginosa
ceftazidime/avibactam	2	8	0.03 to ≥256	93.9	6.1
imipenem	2	≥16	0.25 to ≥16	68.8	31.2
meropenem	0.5	≥16	0.03 to ≥16	70.2	19.9
colistin	1	2	≤0.06 to ≥16	99.4	0.6
amikacin	4	32	0.5 to ≥64	86.4	10.1
MDR (N = 110)
ceftazidime/avibactam	8	32	0.25 to ≥256	80.9	19.1
imipenem	≥16	≥16	0.5 to ≥16	28.2	71.8
meropenem	≥16	≥16	0.06 to ≥16	30.0	57.3
colistin	1	2	≤0.06 to 2	100	0.0
amikacin	8	≥64	0.5 to ≥64	65.5	30.9
Chile (N = 304)
All P. aeruginosa
ceftazidime/avibactam	4	32	0.25 to ≥256	75.0	25.0
imipenem	4	≥16	0.5 to ≥16	50.0	50.0
meropenem	2	≥16	0.06 to ≥16	52.0	33.2
colistin	1	2	0.25 to 4	99.7	0.3
amikacin	8	≥64	≤0.25 to ≥64	68.4	26.3
MDR (N = 162)
ceftazidime/avibactam	8	64	1 to ≥256	53.1	46.9
imipenem	≥16	≥16	1 to ≥16	14.2	85.8
meropenem	≥16	≥16	0.12 to ≥16	17.3	62.3
colistin	1	2	0.25 to 4	99.4	0.6
amikacin	16	≥64	2 to ≥64	46.3	45.7
Colombia (N = 225)
All P. aeruginosa
ceftazidime/avibactam	2	16	0.12 to 128	86.7	13.3
imipenem	2	≥16	0.25 to ≥16	68.4	31.6
meropenem	0.5	≥16	0.03 to ≥16	68.4	23.6
colistin	1	1	≤0.06 to ≥16	99.6	0.4
amikacin	4	≥64	≤0.25 to ≥64	82.2	14.7
MDR (N = 79)
ceftazidime/avibactam	8	64	0.12 to 128	62.0	38.0
imipenem	≥16	≥16	0.25 to ≥16	29.1	70.9
meropenem	≥16	≥16	0.03 to ≥16	29.1	63.3
colistin	1	2	0.12 to 2	100	0.0
amikacin	8	≥64	1 to ≥64	54.4	40.5
Mexico (N = 524)
All P. aeruginosa
ceftazidime/avibactam	2	64	0.03 to ≥256	85.1	14.9
imipenem	2	≥16	0.12 to ≥16	62.2	37.8
meropenem	1	≥16	≤0.004 to ≥16	62.2	23.1
colistin	1	2	0.12 to 8	98.1	1.9
amikacin	4	≥64	≤0.25 to ≥64	74.2	20.8
MDR (N = 169)
ceftazidime/avibactam	8	≥256	1 to ≥256	54.4	45.6
imipenem	≥16	≥16	0.12 to ≥16	18.9	81.1
meropenem	≥16	≥16	0.12 to ≥16	14.2	69.2
colistin	1	2	0.12 to 4	96.4	3.6
amikacin	32	≥64	0.5 to ≥64	39.1	52.7
Venezuela (N = 309)
All P. aeruginosa
ceftazidime/avibactam	2	32	0.12 to ≥256	83.2	16.8
imipenem	2	≥16	0.25 to ≥16	70.9	29.1
meropenem	0.5	≥16	0.03 to ≥16	68.6	23.3
colistin	1	1	0.25 to 4	99.7	0.3
amikacin	4	≥64	1 to ≥64	74.4	21.4
MDR (N = 91)
ceftazidime/avibactam	32	64	0.5 to ≥256	42.9	57.1
imipenem	≥16	≥16	1 to ≥16	18.7	81.3
meropenem	≥16	≥16	0.12 to ≥16	9.9	76.9
colistin	1	1	0.5 to 2	100	0.0
amikacin	≥64	≥64	1 to ≥64	19.8	69.2

R, resistant; S, susceptible.

^aINFORM was succeeded by ATLAS in 2018.